Пентакард-10 is generally used for the sustained, long-term management of certain chronic heart and circulatory conditions. The therapy supports the management of conditions marked by increased physiological stress and is considered relevant in contexts involving heightened systemic burden. Therapeutic application includes key domains, specifically: essential hypertension (high blood pressure), chronic stable angina pectoris (chest pain), and the supportive treatment of certain types of chronic stable heart failure.

In these clinical scenarios, the medication helps address symptom clusters that may become disruptive. For instance, in managing chronic stable angina, it assists with easing symptoms related to heightened physiological activity, which may assist with easing symptoms that become more disruptive during flare-ups. The supportive management provided is also relevant for managing a rapid or irregular pulse in certain cardiac arrhythmias, which assists with maintaining functional stability and supports general well-being during symptomatic periods.

---

Quick Fact: Supportive Relief for Symptoms

Пентакард-10 supports patients by easing the overall symptom burden associated with heart conditions and helps maintain a sense of stability in situations where patients experience symptoms that interfere with daily functioning.

Eligibility for Пентакард-10 (Bisoprolol Fumarate)

This medicine is officially approved for use in adults who are managing conditions such as Hypertension, Chronic Stable Angina Pectoris, and Stable Chronic Heart Failure. Eligibility is strictly defined by regulatory guidelines to ensure patient safety and appropriate use.

---

Absolute Contraindications (Must Not Use)

Use of Bisoprolol Fumarate is strictly contraindicated in individuals with certain severe acute conditions, including Cardiogenic Shock, Acute Heart Failure or decompensation requiring intravenous support, Severe Bradycardia, Second- or Third-Degree AV Block (without a pacemaker), Severe Bronchial Asthma, and Metabolic Acidosis.

---

Age and Condition-Based Restrictions

Population/Condition	Regulatory Status
Pediatric Population (under 18)	Not recommended; safety and efficacy are not established due to insufficient data.
Severe Renal/Hepatic Impairment	Use is permitted but the dose is restricted and generally should not exceed 10 mg daily.
Pregnancy/Lactation	Not recommended; use during pregnancy should only be if clearly needed, and breastfeeding is not advised.

Special caution is also required for patients with Diabetes Mellitus or mild bronchospastic disease, as the medicine may mask certain symptoms.

Interactions with other medicines and products

The official regulatory profile for Пентакард-10 (Bisoprolol Fumarate) defines specific interaction patterns, constraints, and prohibitions detailed in government prescribing information. The clearance of Bisoprolol is achieved equally through renal excretion and non-renal (hepatic oxidative metabolism). This elimination profile is relevant for patients with severe renal or hepatic impairment, where a documented risk of reduced clearance requires that the maximum daily dosage not exceed 10 mg.

Interaction Restrictions and Specific Combinations

Certain combinations are officially restricted or prohibited due to documented pharmacodynamic risks:

• Contraindicated Combinations: Co-administration with Floctafenine or Sultopride is contraindicated due to the documented risk of severe cardiovascular events or ventricular arrhythmia.
• Non-Recommended Combinations: Concomitant use with other beta-blocking agents or certain calcium antagonists (Verapamil or Diltiazem types) is generally not recommended due to additive negative effects on myocardial contractility and AV conduction.

Timing and Procedural Constraints

Specific administration rules govern the use of certain interacting agents:

• Clonidine Discontinuation: If a centrally-acting antihypertensive like Clonidine is being withdrawn, Bisoprolol Fumarate must be discontinued several days before the withdrawal of Clonidine is initiated to prevent rebound hypertension.
• Absorption Interference: The official label notes that Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) may cause a decreased hypotensive effect through pharmacodynamic antagonism. Alcohol may also result in documented additive effects in lowering blood pressure.

How Пентакард-10 Works: Mechanism of Action

The drug functions as a prodrug that undergoes metabolic transformation, resulting in the release of Nitric Oxide (NO) within the vascular endothelium and adjacent tissues. This NO acts as a signaling molecule, diffusing rapidly to smooth muscle cells where it activates the cytosolic enzyme soluble guanylate cyclase (sGC). Activation of sGC increases the intracellular concentration of the second messenger, cyclic Guanosine Monophosphate (cGMP). Elevated cGMP levels initiate a phosphorylation cascade that leads to the deactivation of the contractile apparatus within the vascular smooth muscle cells, resulting in tissue relaxation (vasodilation). This systemic vasodilation causes a reduction in the volume of blood returning to the heart (preload) and decreases the resistance the heart ejects against (afterload). These hemodynamic adjustments collectively alter the relationship between myocardial oxygen supply and myocardial oxygen demand, representing the primary physiological modulation of the mechanism.

Administration Guidelines for Bisoprolol Fumarate

Пентакард-10, containing Bisoprolol Fumarate, is administered via the oral route as a film-coated tablet. The medicine is taken once daily (qDay), preferably in the morning, and standard instructions indicate it can be consumed with or without food. Tablets should be swallowed whole with liquid and generally not chewed or crushed; however, scored tablets may be divided for precise dose adjustments.

---

Dosing and Titration Schedules

Standard dosing varies based on the chronic condition being managed, but regimens adhere to a long-term maintenance pattern. For the management of hypertension and chronic stable angina, treatment typically initiates at 5 mg once daily, with the dose adjusted up to a maximum of 20 mg per day.

For chronic stable heart failure, a specific, supervised titration phase is required. Treatment begins at the dose of 1.25 mg once daily, with the dose subsequently gradually doubled at weekly intervals up to a target maximum of 10 mg once daily, if well tolerated. This uptitration process is performed under specialist observation to ensure procedural stability.

---

Procedural Constraints and Cessation

In populations with severe renal or hepatic impairment, the total daily dose must not exceed 10 mg. For older adults, no mandatory adjustment is required, but starting with the lowest possible dose is noted. If a dose is forgotten, it should be taken as soon as remembered, unless it is nearly time for the next scheduled dose, in which case the missed dose is skipped; a double dose must never be taken. Furthermore, treatment is typically long-term and must never be stopped abruptly; established protocols require a gradual tapering process over one to two weeks to avoid acute deterioration.

Пентакард-10: Recent Clinical Evidence

The available evidence for Bisoprolol Fumarate (Пентакард-10) describes the types of clinical studies that have been conducted and the high-level measurements that were monitored. This overview is solely for informational purposes and describes the structure of the research base, not individual clinical results.

---

Evidence for Use in Essential Hypertension (High Blood Pressure)

The research landscape includes short-term randomized controlled trials (RCTs) and systematic reviews exploring the agent's use in managing blood pressure. These studies focused on outcomes monitoring physiological strain, particularly the change in systolic and diastolic blood pressure (SBP/DBP) measurements and shifts in heart rate. Studies also monitored the percentage of participants whose blood pressure values were observed to fall within pre-defined ranges. Findings were based on monitoring these blood pressure changes.

---

Evidence for Use in Chronic Stable Heart Failure (Supportive Treatment)

The evidence base for its supportive use is characterized by large-scale, long-term, multicenter, placebo-controlled randomized outcome trials. Outcomes monitored included all-cause mortality, cardiovascular mortality, the frequency of hospital admissions related to phases of heightened symptom activity, and changes in the heart's functional status (e.g., ejection fraction). The trials included adult patients with systolic dysfunction, often with functional limitations.

---

Long-Term Studies and Research Gaps

The major trials studying this agent in chronic heart failure involved long-term follow-up extending over several years. This contrasts with studies for hypertension and angina pectoris, which often focused on intermediate-term changes (e.g., 12 weeks). Therefore, long-term effects are not fully established across all indications through the primary studies. Additionally, data for certain groups remain insufficient, such as in pediatric patients, and comparative evidence is limited against all alternative treatments.

Key Studies & References

1. The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial
2. AHA/ACC/HFSA Guideline for the Management of Heart Failure (2022) - Referenced Summary

Common questions about Пентакард-10 (FAQ)

---

Q: What should I do if my blood pressure feels too low while taking this drug?

Regulatory documents state that symptoms of low blood pressure (hypotension) may occur. These signs can include dizziness, feeling lightheaded, or fainting. If these signs or symptoms occur, it is important to contact a healthcare provider for medical guidance regarding continued use.

---

Q: What other conditions is Bisoprolol used to treat besides high blood pressure?

According to official product information, this medicine is approved to treat more than just high blood pressure. The official indications include the management of Hypertension (high blood pressure), Stable Chronic Angina Pectoris (a type of chest pain), and Stable Chronic Heart Failure (as a supportive treatment).

---

Q: How long does it typically take for Bisoprolol to start working to lower my blood pressure?

Studies and official information indicate that the drug begins to have initial effects, such as a reduced heart rate, within a few hours of the first dose. However, the full, consistent blood pressure-lowering effect may take longer, often up to two weeks of continuous therapy, to be fully established.

---

Q: What are the potential signs of an overdose?

Regulatory documentation on beta-blocker toxicity notes that signs of an overdose can be serious. Symptoms may include a severely slow heart rate (bradycardia), very low blood pressure (hypotension), difficulty breathing, and confusion or dizziness. If overdose symptoms are suspected, seek immediate emergency medical help.

---

Q: Can I crush or split the Bisoprolol tablet?

Official administration guidelines state that the film-coated tablets should generally be swallowed whole and not chewed or crushed. However, certain strengths of the tablet are manufactured with a score (a line in the middle) and can be halved if a dose adjustment is necessary. Consultation with the prescribing healthcare professional is recommended to determine the appropriate procedure for a specific tablet.

---

Q: Will Bisoprolol affect my ability to drive?

Official information advises caution, as common side effects like dizziness, headache, or fatigue can occur, particularly when starting treatment or changing doses. Since these effects may impair concentration and reaction time, patients are generally advised to use caution and refrain from activities like driving or operating machinery until they understand the medicine's effect.

---

Q: Does the 10 mg strength mean this drug is the most powerful dose?

According to regulatory documentation, the 10 mg strength is often used as the maximum maintenance dose for chronic stable heart failure. For the management of high blood pressure or angina, the dose can be adjusted up to a maximum of 20 mg per day, which is the highest dosage strength mentioned in official documents.

Official Storage and Disposal Requirements

Storage and disposal of Пентакард-10 (Bisoprolol Fumarate) must adhere strictly to the conditions specified in official regulatory labeling to ensure product quality.

Requirement Area	Official Instructions
Temperature	Store below 25 C (77 F). Do not refrigerate or freeze the tablets.
Protection	Keep the tablets protected from light and moisture by storing them in the original container or outer carton.
Child Safety	Store the product out of the sight and reach of children to prevent accidental ingestion.
Disposal	Dispose of unused or expired medicine according to local regulations. Do not throw the medicine away via wastewater (e.g., down a toilet or sink) or household waste.

These instructions define the mandatory environmental constraints and handling rules for the product as documented in governmental labeling.